Why Blood Cancer United’s luveltamab move could change rare pediatric cancer access
Find out how Blood Cancer United’s luveltamab access move could reshape rare pediatric AML drug rescue models.
Pharma & Biotech
Pharma & Biotech
GenSight Biologics begins LHON treatment under France compassionate access as REVISE Phase II moves forward
GenSight Biologics begins treating ND4-LHON patients under France's AAC compassionate access program. Analyse what REVISE and AAC mean for the regulatory pathway.
Medical Devices & Diagnostics
How Mitria Medical’s nitinol spacer challenges the edge-to-edge repair model for functional mitral regurgitation
Mitria Medical's Subvalvular Spacer reaches the U.S. under FDA compassionate use. What it means for FMR patients and what clinical evidence still needs to come.
Pharma & Biotech
What GenSight Biologics’ French CUA decision means for LHON gene therapy
France grants compassionate use access to GenSight Biologics’ LUMEVOQ for LHON. Explore what this decision changes and what risks remain.